{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T16:51:39Z","timestamp":1783356699024,"version":"3.54.6"},"reference-count":13,"publisher":"SAGE Publications","issue":"12","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Endourology"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>\n                      To compare the clinical outcomes and complication rates of convective water vapor energy ablation (Rezum\n                      <jats:sup>\u00ae<\/jats:sup>\n                      ) and prostatic urethral lift (Urolift\n                      <jats:sup>\u00ae<\/jats:sup>\n                      ). To identify predictive factors for treatment failures in both treatments.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials &amp; Methods:<\/jats:title>\n                    <jats:p>\n                      Prospective clinico-epidemiological data of patients who underwent Urolift\n                      <jats:sup>\u00ae<\/jats:sup>\n                      or Rezum\n                      <jats:sup>\u00ae<\/jats:sup>\n                      in a single institution for benign prostatic hyperplasia (BPH) was collected. The choice of intervention depended on the preference of the patients after patient-centric discussions.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      From October 2019 to October 2022, 86 patients underwent Rezum\n                      <jats:sup>\u00ae<\/jats:sup>\n                      , and 62 patients underwent Urolift\n                      <jats:sup>\u00ae<\/jats:sup>\n                      . Rezum\n                      <jats:sup>\u00ae<\/jats:sup>\n                      involved a longer indwelling catheter duration (12.38\u2009\u00b1\u20095.548\n                      <jats:italic toggle=\"yes\">vs<\/jats:italic>\n                      1.39\u2009\u00b1\u20093.010 days,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      &lt; 0.001) compared with Urolift\n                      <jats:sup>\u00ae<\/jats:sup>\n                      . Rezum\n                      <jats:sup>\u00ae<\/jats:sup>\n                      was associated with more complications compared with Urolift\n                      <jats:sup>\u00ae<\/jats:sup>\n                      (36 [41.9%]\n                      <jats:italic toggle=\"yes\">vs<\/jats:italic>\n                      10 [16.1%] cases,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      &lt; 0.001). Rezum\n                      <jats:sup>\u00ae<\/jats:sup>\n                      had more cases of hematuria (17 [19.8%]\n                      <jats:italic toggle=\"yes\">vs<\/jats:italic>\n                      4 [6.5%] cases [\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      = 0.022]) and urinary tract infections (27 [31.4%]\n                      <jats:italic toggle=\"yes\">vs<\/jats:italic>\n                      3 [4.8%] cases,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      &lt; 0.001) compared with Urolift\n                      <jats:sup>\u00ae<\/jats:sup>\n                      . There were no significant differences in Clavien\u2013Dindo Grade 3\u20135 complications between the interventions. Urolift\n                      <jats:sup>\u00ae<\/jats:sup>\n                      was associated with higher reoperation rates (5 [8.1%]\n                      <jats:italic toggle=\"yes\">vs<\/jats:italic>\n                      0 [0%] cases,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      = 0.010) compared Rezum\n                      <jats:sup>\u00ae<\/jats:sup>\n                      . Rezum\n                      <jats:sup>\u00ae<\/jats:sup>\n                      had higher anticholinergic usage rates compared with Urolift\n                      <jats:sup>\u00ae<\/jats:sup>\n                      post-operation (22 [25.6%]\n                      <jats:italic toggle=\"yes\">vs<\/jats:italic>\n                      8 [12.9%] cases,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      = 0.024). Both interventions showed improvement in the International Prostate Symptom Score (IPSS), quality of life score, and peak velocity flow over the 2 years with no significant difference between the two. Based on receiver operating characteristic curve, preoperation IPSS \u226516 had 95.7% sensitivity and 38.4% specificity to predict the probability of treatment failures after the interventions.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>\n                      There was no difference in clinical outcomes of patients who underwent Rezum\n                      <jats:sup>\u00ae<\/jats:sup>\n                      and Urolift\n                      <jats:sup>\u00ae<\/jats:sup>\n                      . However, patients who had undergone Rezum\n                      <jats:sup>\u00ae<\/jats:sup>\n                      faced more minor complications and more required anti-cholinergic medications. Lastly, physicians should note that patients with IPSS \u226516 would unlikely benefit from either intervention.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/end.2024.0400","type":"journal-article","created":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T08:21:59Z","timestamp":1726820519000},"page":"1387-1394","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":8,"title":["Convective Water Vapor Energy Ablation (Rezum\n                    <sup>\u00ae<\/sup>\n                    ) Versus Prostatic Urethral Lift (Urolift\n                    <sup>\u00ae<\/sup>\n                    ): A 2-Year Prospective Study"],"prefix":"10.1177","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5277-7511","authenticated-orcid":false,"given":"Yu Xi Terence","family":"Law","sequence":"first","affiliation":[{"name":"Department of Urology, National University Hospital, Singapore, Singapore."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei Jing Kelven","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Urology, National University Hospital, Singapore, Singapore."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Shen","sequence":"additional","affiliation":[{"name":"Biostatistics Unit, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyaw","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Urology, National University Hospital, Singapore, Singapore."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chloe Shu Hui","family":"Ong","sequence":"additional","affiliation":[{"name":"Department of Urology, National University Hospital, Singapore, Singapore."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi Yang","family":"Lim","sequence":"additional","affiliation":[{"name":"Department of Urology, National University Hospital, Singapore, Singapore."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory Xiang Wen","family":"Pek","sequence":"additional","affiliation":[{"name":"Department of Urology, National University Hospital, Singapore, Singapore."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woon Chau","family":"Tsang","sequence":"additional","affiliation":[{"name":"Department of Urology, National University Hospital, Singapore, Singapore."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi Quan","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Urology, National University Hospital, Singapore, Singapore."},{"name":"Division of Urology, Ng Teng Fong General Hospital, Singapore, Singapore."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun Yang","family":"Chia","sequence":"additional","affiliation":[{"name":"Department of Urology, National University Hospital, Singapore, Singapore."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"King Chien Joe","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Urology, National University Hospital, Singapore, Singapore."},{"name":"Asian Healthcare Specialist, Mount Alvernia, Singapore, Singapore."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei Jin","family":"Chua","sequence":"additional","affiliation":[{"name":"Department of Urology, National University Hospital, Singapore, Singapore."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,12,1]]},"reference":[{"key":"e_1_3_5_2_2","article-title":"Non-neurogenic male Lower Urinary Tract Symptoms (LUTS), incl. Benign Prostatic Obstruction (BPO)","author":"Cornu JN","year":"2023","unstructured":"Cornu JN, , Gacci M, , Hashim H, et al. Non-neurogenic male Lower Urinary Tract Symptoms (LUTS), incl. Benign Prostatic Obstruction (BPO). EAU Guideline, 2023.","journal-title":"EAU Guideline"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12894-020-00776-2"},{"issue":"3","key":"e_1_3_5_4_2","first-page":"8802","article-title":"Five year results of the prospective randomized controlled prostatic urethral L.I.F.T. Study","volume":"24","author":"Roehrborn CG","year":"2017","unstructured":"Roehrborn CG, , Barkin J, , Gange SN, et al. Five year results of the prospective randomized controlled prostatic urethral L.I.F.T. Study. Can J Urol, 2017; 24(3):8802\u20138813.","journal-title":"Can J Urol"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000001778"},{"issue":"5","key":"e_1_3_5_6_2","first-page":"10824","article-title":"Prostatic urethral lift (UroLift) versus convective water vapor ablation (Rezum) for minimally invasive treatment of BPH: A comparison of improvements and durability in 3-year clinical outcomes","volume":"28","author":"Elterman D","year":"2021","unstructured":"Elterman D, , Shepherd S, , Saadat SH, et al. Prostatic urethral lift (UroLift) versus convective water vapor ablation (Rezum) for minimally invasive treatment of BPH: A comparison of improvements and durability in 3-year clinical outcomes. Can J Urol, 2021; 28(5):10824\u201310833.","journal-title":"Can J Urol"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11255-021-02899-3"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1089\/end.2022.0385"},{"issue":"3","key":"e_1_3_5_9_2","first-page":"10213","article-title":"Early patient experience following treatment with the UroLift prostatic urethral lift and Rezum steam injection","volume":"27","author":"Tutrone RF","year":"2020","unstructured":"Tutrone RF, , Schiff W. Early patient experience following treatment with the UroLift prostatic urethral lift and Rezum steam injection. Can J Urol, 2020; 27(3):10213\u201310219.","journal-title":"Can J Urol"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-018-0118-x"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2018.12.041"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.31491\/UTJ.2024.06.019"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2023.06.013"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2021.11.010"}],"container-title":["Journal of Endourology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/end.2024.0400","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/end.2024.0400","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/end.2024.0400","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T20:15:44Z","timestamp":1777407344000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/end.2024.0400"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":13,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["10.1089\/end.2024.0400"],"URL":"https:\/\/doi.org\/10.1089\/end.2024.0400","relation":{},"ISSN":["0892-7790","1557-900X"],"issn-type":[{"value":"0892-7790","type":"print"},{"value":"1557-900X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12]]}}}